| European Case Law Identifier: | ECLI:EP:BA:2017:R000515.20170529 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 29 May 2017 | ||||||||
| Case number: | R 0005/15 | ||||||||
| Petition for review of: | T 1938/09 | ||||||||
| Application number: | 98906678.2 | ||||||||
| IPC class: | A61F 13/00 A61K 31/485 A61K 9/70 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | B | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Sustained analgesia achieved with transdermal delivery of buprenorphine | ||||||||
| Applicant name: | EURO-CELTIQUE S.A. | ||||||||
| Opponent name: | Hexal AG Luye Pharma AG |
||||||||
| Board: | EBA | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Right to be heard  fundamental violation (no) Omission to decide on a relevant request (no) Other fundamental procedural defect (no) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/r150005eu1.html
Date retrieved: 17 May 2021